Pegloticase

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout

A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)

Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy

Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout

Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney Transplant

Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout

Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect

Observational Study of the Use of Pegloticase (KRYSTEXXA®) in Refractory Chronic Gout

Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout

Study to Assess Pegloticase (KRYSTEXXA®) in Patients on Hemodialysis

Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout

Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout